HoldsUp

The Diary Of A CEO · 2026-04-20 · Steven Bartlett (host), Alex Tatem

Peptide Expert: What Do Peptides Actually Do? (EXPLAINED) - Dr Alex Tatem

61 research-tied claims examined: 3 contradicted 8 overstated 45 supported 5 unverified

3

Contradicted by research

0:29:08Alex Tatemcontradictedhigh

Tirzepatide produces more weight loss per milligram than any other commercially available GLP-1 drug.

"So, Mounjaro is the brand name for tirzepatide, all right? Tirzepatide being the leading GLP-1 product right now from Lilly. So, this produces more weight loss per milligram than any other product that we've got out right now." (said at 0:29:08)

The claim that tirzepatide produces more weight loss per milligram than any other GLP-1 drug is contradicted by clinical trial data. While tirzepatide yields greater overall (total) weight loss at its maximal clinical doses (10 mg to 15 mg weekly) than semaglutide at its approved doses (1.0 mg to 2.4 mg weekly), semaglutide is substantially more potent on a per-milligram basis. For example, in head-to-head phase 3 clinical trials, semaglutide 2.4 mg weekly achieves approximately 13% to 15% body weight reduction (~5.4% weight loss per milligram), whereas tirzepatide 15 mg weekly achieves approximately 20% body weight reduction (~1.3% weight loss per milligram). Similarly, in the SURPASS-2 trial comparing tirzepatide (5 mg, 10 mg, 15 mg) to semaglutide (1 mg), semaglutide produced 5.7 kg weight loss (5.7 kg/mg) versus 7.6 kg to 11.2 kg weight loss for tirzepatide (0.75 kg/mg to 1.52 kg/mg).

0:45:14Alex Tatemcontradictedhigh

Roledumab and trevogrumab are monoclonal antibody myostatin inhibitors designed to maintain muscle mass in a caloric deficit.

"And then you have roledumab and trevogrumab, which are two other compounds owned by different pharmaceutical company that are all designed to maintain muscle even in a significant caloric deficit." (said at 0:45:14)

The claim incorrectly identifies roledumab as a muscle-maintaining myostatin inhibitor. While trevogrumab is indeed a monoclonal antibody that targets myostatin and activin signaling to preserve lean body mass during weight loss, roledumab is actually a recombinant monoclonal anti-RhD antibody developed to prevent RhD allo-immunization in Rh-negative individuals, with no role or design in myostatin inhibition or muscle preservation.

1:25:43Alex Tatemcontradictedhigh

Oral erectile dysfunction medications fail in approximately 15% of men on initial use.

"And if you look at statistics, the oral medications are going to fail in 15% of those men the first time they feel that." (said at 1:25:43)

Published systematic reviews and clinical trial data indicate that the non-response or failure rate for oral phosphodiesterase type 5 inhibitors (PDE5is) in erectile dysfunction is approximately 30% to 40%, not 15%. Initial failure rates in clinical practice can be even higher before proper dose titration, timing adjustments, and patient education (e.g., ensuring adequate sexual stimulation and avoiding heavy meals).

8

Overstated

0:25:17Alex Tatemoverstatedvery low

TB-500 promotes blood flow and tissue repair at injury sites.

"And then we have the brother to that which is TB-500, this vial over here. This improves blood flow to an injured area. You could think of this as sending the soldiers, as sending the cells that are required for rebuilding that tissue matrix that was damaged by a tear or a cut, all right?" (said at 0:25:17)

TB-500 (a synthetic peptide fragment derived from the active site of thymosin beta-4, Ac-LKKTETQ) and full-length thymosin beta-4 have demonstrated pro-angiogenic, cell migration, and tissue repair properties in preclinical in vitro and animal models (such as rat tendon repair and wound healing models). However, rigorous clinical trial data evaluating the safety and efficacy of TB-500 for tissue repair or blood flow enhancement in humans are lacking, and the compound remains unapproved for clinical use in musculoskeletal injuries.

0:25:48Alex Tatemoverstatedvery low

MOTS-c improves VO2 max and exercise tolerance by upregulating energy pathways and increasing ATP production.

"We're also getting MOTS-c, and you know, some people just will call it exercise in a vial. It improves your VO2 max and your exercise tolerance, and by upregulating the energy pathway, basically making more ATP, the energy that we all use to move, it makes more of that available, all right?" (said at 0:25:48)

The claim that exogenous MOTS-c improves VO2 max, enhances exercise tolerance, and increases available ATP in humans is overstated. Preclinical animal research shows that MOTS-c administration can enhance treadmill running performance and physical capacity in young and aging mice, and modulate skeletal muscle bioenergetics via AMPK and PGC-1α pathways. However, in humans, evidence is limited to observational studies showing that endogenous MOTS-c increases in response to exercise and correlates with lower-body muscle strength, but does not correlate with maximal oxygen uptake (peak VO2). There are no clinical trials demonstrating that administering MOTS-c improves VO2 max or exercise capacity in humans.

0:26:12Alex Tatemoverstatedlow

Semax improves cognitive function.

"We're also going to get DSIP, Epithalon, and Semax, which are all peptides that affect cognitive function. So, improving thinking, like Semax is a great option for that." (said at 0:26:12)

Semax (a synthetic ACTH 4-10 analogue developed in Russia) has demonstrated neurotrophic and neuroprotective properties in animal models, functional recovery benefits in stroke patients, and altered resting-state default mode network connectivity in small human imaging studies. However, robust, high-quality randomized controlled trials confirming cognitive enhancement or improved cognitive performance in healthy humans are lacking. Describing Semax as a 'great option' for improving thinking overstates the strength, scale, and generalizability of the available human clinical evidence.

0:00:56Alex Tatemoverstatedvery low

GHK-Cu is a peptide that improves skin complexion, skin quality, hair, and nails.

"So, this is probably the most well-known peptide for skin complexion, and it improves quality of hair and nails... We have peptides that can improve skin quality like GHK-Cu." (said at 0:00:56)

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is widely used in cosmetic formulations and has in vitro and animal evidence demonstrating stimulation of collagen synthesis, wound repair, and hair follicle enlargement, along with limited cosmetic studies reporting modest improvements in skin elasticity and fine lines. However, rigorous clinical trial evidence in humans remains sparse, and there is no established published clinical evidence demonstrating that GHK-Cu improves nail quality.

0:38:38Alex Tatemoverstatedhigh

GLP-1 receptor agonist medications slow gastric emptying, thereby reducing post-meal glucose spikes and significantly increasing insulin sensitivity.

"Because what you're doing is you are slowing gastric emptying and so you have a slower absorption of that bolus of food that you've eaten, so your glucose doesn't spike. And so, as a result, that increases insulin sensitivity significantly." (said at 0:38:38)

GLP-1 receptor agonists do slow gastric emptying and reduce postprandial glucose excursions by delaying the systemic appearance of ingested glucose. However, attributing significant increases in insulin sensitivity directly as a result of delayed gastric emptying overstates the mechanical link. While GLP-1 receptor agonists can improve peripheral insulin sensitivity, these improvements are primarily mediated by long-term weight loss and tissue-specific molecular mechanisms rather than being a direct consequence of slowed gastric emptying.

0:42:15Alex Tatemoverstatedvery low

Delta sleep-inducing peptide (DSIP) has been shown to help regulate circadian rhythms.

"So, if we look at DSIP, okay? That has been shown to be helpful with regulating your circadian rhythm." (said at 0:42:15)

Delta sleep-inducing peptide (DSIP) is a neuropeptide originally isolated in the 1970s for its ability to induce slow-wave (delta) sleep in animals. While endogenous DSIP exhibits a diurnal rhythm (peaking in the daytime and dropping at sleep onset in correlation with body temperature) and some animal experiments have observed that DSIP's physiological effects (e.g., on body temperature and blood pressure) depend on the phase of the circadian cycle, there is no robust clinical or experimental evidence demonstrating that DSIP administration regulates or resets human circadian rhythms. Claiming that DSIP has been shown to help regulate circadian rhythms overstates preliminary, descriptive physiological and animal data.

1:00:52Alex Tatemoverstatedvery low

Epithalon shows benefits in healing parts of the brain associated with regulating the circadian rhythm.

"it does show some benefits when it comes to, you know, healing parts of your brain that are, you know, associated with regulating your circadian rhythm." (said at 1:00:52)

Epithalon (epitalon), a synthetic tetrapeptide modeled on pineal gland peptide extracts, has been studied for its effects on pineal gland function and circadian endocrine secretion. Small animal models (aged rhesus monkeys and rodents) and preliminary human observations from a single research group reported that epitalon administration restored nighttime melatonin secretion and normalized the circadian rhythm of melatonin production. However, evidence demonstrating that epitalon structurally 'heals' brain regions responsible for circadian regulation (such as the suprachiasmatic nucleus or pineal gland) is lacking; the literature shows functional modulation of melatonin rhythms rather than structural tissue repair, and the findings have not been replicated in large, rigorous, independent randomized controlled trials.

1:18:55Alex Tatemoverstatedhigh

MRIs of soldiers returning from war demonstrate degeneration of the hippocampus.

"there's a part in the brain called the hippocampus that when they do MRIs on soldiers that come back from war, that'll be degenerated in them." (said at 1:18:55)

Structural magnetic resonance imaging (MRI) studies and large-scale meta-analyses demonstrate that combat exposure and combat-related posttraumatic stress disorder (PTSD) are associated with reduced hippocampal volume. A twin study in Vietnam veterans found an 11% smaller right hippocampal volume in twin brothers with combat-related PTSD compared to their unexposed twin brothers without PTSD. However, the claim overstates this finding by implying that hippocampal degeneration is a universal outcome for all soldiers returning from war; research shows that smaller hippocampal volume is specifically associated with chronic or unremitting PTSD, high perceived threat, or vulnerability to PTSD, rather than being present in all returning service members regardless of clinical status.

45

Supported by research

0:01:09Alex Tatemsupportedmoderate

Melanotan II induces a deep tan in response to low amounts of ultraviolet sun exposure and causes erections.

"Next, Melanotan II. And this will actually end up giving you a deep tan in response to just a little bit of UV sun exposure. It'll also give you some of the most impressive erections you've ever had in your life, so be warned." (said at 0:01:09)

Melanotan II (MT-II) is a synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). In early human phase I clinical testing, subcutaneous administration of MT-II stimulated melanin pigmentation (tanning) and unexpectedly induced spontaneous penile erections lasting 1 to 5 hours. Subsequent investigations confirmed its potent pro-erectile effects mediated through central melanocortin receptors (which later led to the development of related peptides like bremelanotide for sexual dysfunction).

0:05:03Alex Tatemsupportedhigh

Insulin was the first peptide isolated and used in medicine in 1921.

"The first peptide that was actually isolated and used in medicine was insulin back in 1921." (said at 0:05:03)

Historical and biomedical literature confirms that insulin—a 51-amino-acid peptide hormone—was first successfully isolated from pancreatic tissue in 1921 by Frederick Banting and Charles Best at the University of Toronto. It subsequently became the first purified peptide hormone used therapeutically in clinical medicine (first administered to a human patient in early 1922).

0:05:09Alex Tatemsupportedhigh

Lupron was introduced in 1985 as a peptide designed to shut down testosterone production for prostate cancer patients.

"And then, all the way in 1985, in the world of urology, which is where I was trained, we had Lupron, which is a different peptide that, again, also a peptide like insulin, but instead of having wide-ranging metabolic effects, it had an endocrine effect. It was designed to shut down the production of testosterone for prostate cancer patients that needed to have their testosterone taken away." (said at 0:05:09)

Lupron (leuprolide acetate) is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH). It received FDA approval in 1985 for the treatment of advanced prostate cancer, functioning as androgen deprivation therapy by suppressing pituitary gonadotropin release and shutting down testicular testosterone production.

0:07:07Alex Tatemsupportedvery low

BPC-157 is a synthetic version of a naturally occurring gastric peptide that enhances blood vessel growth in areas of injury.

"BPC-157 is a synthetic version of a naturally found peptide in the gut. But what this actually does is it enhances blood vessel growth in areas of injury." (said at 0:07:07)

Body Protection Compound-157 (BPC-157) is a synthetic 15-amino acid pentadecapeptide derived from a naturally occurring protein isolated from human gastric juice. Preclinical animal and cellular models consistently demonstrate that BPC-157 promotes angiogenesis (blood vessel growth) in damaged tissues—such as injured muscle, tendon, and granulation tissue—primarily via the upregulation of vascular endothelial growth factor (VEGF) expression and activation of the VEGFR2 and Akt-eNOS pathways. However, evidence supporting its angiogenic and tissue-healing properties is currently derived almost entirely from animal and laboratory studies, with rigorous human clinical trials lacking.

0:07:48Alex Tatemsupportedvery low

Administration of BPC-157 to rats with surgically transected Achilles tendons results in spontaneous tendon healing.

"For example, they have completely transected the Achilles tendon in rats... Transected, so they've cut across the Achilles tendon... And then they administer it to rats and they are healing spontaneously with administration of BPC-157." (said at 0:07:48)

Preclinical animal research supports the claim. In a controlled rat model of complete surgical Achilles tendon transection, daily administration of pentadecapeptide BPC-157 significantly accelerated tendon healing, improved the Achilles functional index, increased biomechanical load capacity, and restored full macroscopic tendon integrity compared with saline controls. Because this evidence is limited entirely to animal and in vitro laboratory models without confirmation from randomized controlled human trials, the certainty of evidence for human efficacy is very low.

0:09:26Alex Tatemsupportedhigh

In 2013, the US Supreme Court ruled in the Myriad Genetics case that naturally occurring human genes (BRCA1 and BRCA2) cannot be patented.

"In 2013, there was actually a court case in the United States. It was called the Myriad Genetics case. This was the company that actually patented the BRCA1 and BRCA2 genes. They discovered the genes that cause breast cancer, all right? ... And the Supreme Court actually sided with that argument, saying that if something is natural, it's found within us, okay? I can't patent, you know, your muscle cells, right?" (said at 0:09:26)

In June 2013, the US Supreme Court issued a unanimous decision in Association for Molecular Pathology v. Myriad Genetics, Inc. (569 U.S. 576), ruling that isolated naturally occurring genomic DNA sequences (specifically the BRCA1 and BRCA2 genes associated with breast and ovarian cancer) are products of nature and not patent-eligible subject matter under 35 U.S.C. § 101 merely because they have been isolated. The Court distinguished naturally occurring genomic DNA from synthetic complementary DNA (cDNA), which remained eligible for patenting because it is not naturally occurring.

0:10:22Alex Tatemsupportedhigh

Around 2012–2013, a compounding pharmacy in New England distributed contaminated specimens that caused an outbreak of fungal meningitis.

"At the same time, I believe it was around 2012, 2013, there was a terrible event that happened in New England where there was a compounding pharmacy that was not doing the right thing, and they ended up having a bunch of contaminated specimens that caused fungal meningitis." (said at 0:10:22)

In 2012–2013, a major multistate outbreak of fungal meningitis and related infections occurred across the United States. Epidemiological investigations traced the outbreak to contaminated lots of injectable methylprednisolone acetate produced by the New England Compounding Center (NECC) in Framingham, Massachusetts. The contamination, predominantly involving the fungus Exserohilum rostratum, resulted in 751 reported cases and 64 deaths, leading to major federal regulatory reforms under the Drug Quality and Security Act of 2013.

0:14:33Alex Tatemsupportedhigh

MK-677 (ibutamoren) is an orally available small molecule that binds to the ghrelin receptor and stimulates growth hormone release and hunger.

"something called MK-677, also known as ibutamoren. So, this is a small molecule, but when a patient takes it, it's orally available. It binds to this receptor called ghrelin, and it actually stimulates the release of significant growth hormone. But what was really interesting is that it would actually stimulate hunger a profound amount." (said at 0:14:33)

MK-677 (ibutamoren mesylate) is an orally bioavailable, non-peptide small molecule that acts as an agonist at the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a). Pharmacological and clinical studies confirm that it mimics the action of ghrelin to potently stimulate pulsatile growth hormone (GH) secretion, elevate downstream IGF-1 levels, and stimulate appetite/hunger.

0:15:30Alex Tatemsupportedhigh

GHRP-2 and GHRP-6 are growth hormone-releasing peptides that stimulate the body's natural release of growth hormone.

"So, GHRP-2 and GHRP-6 were some of the ones we were using at that time. Those are growth hormone-releasing peptides that stimulate the release of your body's natural growth hormone, which can help with tissue repair, can also help with fat loss, and with building muscle." (said at 0:15:30)

GHRP-2 and GHRP-6 are synthetic growth hormone-releasing peptides (ghrelin receptor agonists / growth hormone secretagogues). Extensive endocrinological research in humans and animal models confirms that they bind to specific pituitary and hypothalamic receptors to stimulate the endogenous secretion of growth hormone.

0:15:48Alex Tatemsupportedmoderate

Thymosin beta-4 stimulates angiogenesis and tissue repair.

"We also had BPC-157, and we had derivatives like thymosin beta-4. These are also compounds that can help stimulate angiogenesis, so making new blood vessels, all right, and tissue repair." (said at 0:15:48)

Thymosin beta-4 (Tβ4) is well-established in preclinical research and clinical trials as an actin-sequestering peptide that promotes angiogenesis (new blood vessel formation), endothelial cell migration, and tissue repair/wound healing across various tissue types (such as dermal wounds, corneal injuries, and cardiovascular tissue).

0:26:21Alex Tatemsupportedvery low

DSIP and Epithalon regulate sleep and recovery.

"And then DSIP and Epithalon both have roles in regulating sleep and recovery." (said at 0:26:21)

Preclinical and mechanistic literature supports roles for both Delta Sleep-Inducing Peptide (DSIP) and Epithalon (Epitalon, a synthetic pineal tetrapeptide) in modulating sleep architecture, circadian rhythmicity, and recovery pathways. DSIP has been studied for its ability to promote slow-wave (delta) sleep and restore neurotransmitter balance in animal models of insomnia and stress, while Epithalon directly stimulates pineal melatonin synthesis, telomerase activity, and antioxidant defenses. However, evidence remains limited to preclinical animal and in vitro models, with a lack of robust randomized clinical trials in humans.

0:25:30Alex Tatemsupportedlow

KPV is a peptide that has been linked to angiogenesis and tissue repair.

"On top of that, we're also getting something called KPV. May not have it here, but that is another peptide that has been linked to angiogenesis and tissue repair." (said at 0:25:30)

Preclinical and narrative review literature supports that KPV (Lys-Pro-Val, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone / α-MSH) promotes tissue repair and wound healing, while tripeptides as a class (including KPV formulations) are linked to tissue regeneration, anti-inflammatory activity, and supporting angiogenesis. For example, a 2025 review of tripeptides in wound healing notes that KPV-loaded hydrogels reduce inflammation and promote tissue regeneration, and that tripeptides regulate tissue repair processes including promoting angiogenesis and extracellular matrix remodeling (PMID: 41209547). Preclinical animal models have demonstrated that KPV accelerates tissue repair, such as corneal epithelial wound healing in rabbits (PMID: 16965771) and gut mucosal epithelial barrier recovery in rat models of colitis (PMID: 35245681). However, evidence is largely restricted to in vitro, animal models, and review syntheses rather than robust human clinical trial data, resulting in low certainty.

0:38:53Alex Tatemsupportedhigh

Peptides that increase growth hormone and IGF-1 levels can elevate serum glucose.

"A lot of these peptides that boost growth hormone and boost, let's say, IGF-1, those can actually increase serum glucose and that may not be what you want if you are someone that is trying to work on your insulin sensitivity." (said at 0:38:53)

Randomized controlled trial data confirm that growth hormone secretagogues (such as MK-677) that increase pulsatile growth hormone and IGF-1 levels lead to increases in fasting blood glucose and decreases in insulin sensitivity, consistent with growth hormone's established physiological anti-insulin effects.

0:39:11Alex Tatemsupportedmoderate

Endogenous levels and concentration of the copper tripeptide GHK-Cu decline as humans age.

"And this is interesting because this is a copper tripeptide that has been found to decrease in expression and concentration as we age." (said at 0:39:11)

Endogenous human plasma and serum concentrations of the copper-binding tripeptide GHK (glycyl-L-histidyl-L-lysine, which forms GHK-Cu) decline significantly with age, dropping from an average of approximately 200 ng/mL in healthy young adults (around age 20) to roughly 80 ng/mL in older adults (around age 60).

0:39:27Alex Tatemsupportedmoderate

Topical application of GHK-Cu regenerates skin quality by increasing collagen and elastin production.

"It's been found to be extremely beneficial in regenerating the quality of skin. So, complexion, all right? Increasing the amount of collagen and elastin, the things that we need to keep our faces taut and youthful" (said at 0:39:27)

Topical GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) has been shown in in vitro, animal, and clinical cosmeceutical studies to stimulate the synthesis of collagen, elastin, and glycosaminoglycans, as well as to modulate tissue remodeling enzymes. Published reviews and clinical evaluations indicate that topical application improves skin elasticity, firmness, and fine lines by enhancing extracellular matrix accumulation and dermal regeneration.

0:41:15Alex Tatemsupportedlow

Semax is a 7-amino-acid peptide studied in Russia that demonstrated improved outcomes following traumatic brain injury and stroke.

"And this is one that was originally studied actually in Russia many years ago. And what they found is that this seven-amino acid peptide, when it was administered after a, uh, TBI, so a traumatic brain injury, all right, or acute injury, that patients tended to bounce back faster. Also, they saw evidence of it improving outcomes after stroke." (said at 0:41:15)

Semax is a synthetic heptapeptide (a 7-amino-acid peptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro) developed and researched primarily in Russia as an analogue of ACTH(4-10). Russian preclinical studies and clinical trials have investigated its neuroprotective properties and reported improved functional outcomes, elevated plasma BDNF levels, and accelerated motor recovery following ischemic stroke and acute brain injuries. However, the evidence base consists predominantly of regional, open-label, or relatively small clinical trials and animal models, resulting in low overall GRADE certainty.

0:43:43Alex Tatemsupportedhigh

Exogenous testosterone suppresses fertility in men.

"testosterone, right? But that isn't going to be a good option for our male patients that want to get pregnant cuz testosterone turns off fertility in men" (said at 0:43:43)

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback, reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This drastically lowers intratesticular testosterone production and impairs or halts spermatogenesis, commonly resulting in severe oligospermia or azoospermia. Clinical consensus and guidelines consider exogenous testosterone therapy contraindicated in men seeking to conceive or maintain fertility.

0:45:07Alex Tatemsupportedhigh

Bimagrumab binds to activin receptors to inhibit the myostatin pathway and preserve muscle mass.

"There is one called bimagrumab, which is owned by Lilly. That is going to bind to the peanut butter to myostatin's jelly, which is called activin." (said at 0:45:07)

Bimagrumab is a fully human monoclonal antibody developed to bind competitively to activin type II receptors (ActRIIA and ActRIIB), thereby blocking the downstream signaling of negative muscle regulators including myostatin and activin A. In randomized clinical trials in humans with overweight/obesity and type 2 diabetes, as well as in preclinical models, bimagrumab treatment significantly increased or preserved lean body mass while reducing fat mass.

0:47:35Alex Tatemsupportedhigh

Annual revenue from semaglutide and tirzepatide alone is projected to exceed $55 billion this year.

"Yet the income and the revenue from just semaglutide and tirzepatide alone is going to be over 55 billion this year." (said at 0:47:35)

Published national and global pharmaceutical market analyses confirm that semaglutide (marketed as Ozempic, Wegovy, and Rybelsus) and tirzepatide (marketed as Mounjaro and Zepbound) rapidly grew to become the leading pharmaceutical products by annual expenditure and revenue. Market tracking and expenditure analyses from the IQVIA National Sales Perspectives database identified semaglutide and tirzepatide as the top-selling prescription medications in the United States, driving unprecedented expenditure growth in the endocrine sector and surpassing combined annual revenues of $50–$55+ billion.

0:51:45Alex Tatemsupportedhigh

Tesamorelin stimulates growth hormone release and is uniquely effective at reducing visceral abdominal fat.

"it's a peptide that is commercially available right now. I could write the script for you. You could go pick it up from CVS or Walgreens, okay? This is available as a commercial product. And people really like it because it'll help boost growth hormone, and it happens to be uniquely good at stripping abdominal fat, okay? Or visceral fat." (said at 0:51:45)

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) approved for the reduction of excess abdominal visceral fat in HIV-associated lipodystrophy. Multiple randomized controlled trials, pooled phase 3 studies, and meta-analyses demonstrate that tesamorelin stimulates the release of endogenous growth hormone (increasing IGF-1) and selectively reduces visceral adipose tissue (VAT) without significantly affecting subcutaneous adipose tissue.

0:52:40Alex Tatemsupportedmoderate

Melanotan II is a melanocortin receptor agonist that stimulates skin tanning in response to minimal UV exposure.

"So, this is melanotan II, right? So, this is a melanocortin receptor agonist. So, melanocortin is what makes you tan, right? So, you could administer this, all right? And it will actually end up giving you a deep tan in response to just a little bit of UV sun exposure, all right?" (said at 0:52:40)

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that acts as a melanocortin receptor agonist. Early clinical evaluation confirmed that subcutaneous administration of MT-II stimulates eumelanin synthesis and skin tanning in humans, even after minimal dosing. In related studies evaluating melanotropin analogs in combination with ultraviolet radiation, these peptides significantly enhanced melanin production and tanning with reduced sunlight or UV exposure compared to controls.

0:53:34Alex Tatemsupportedhigh

Bremelanotide (PT-141) is a derivative of Melanotan II available as a prescription medication that provides sexual function benefits without skin tanning.

"there's even a derivative of melanotan II called PT-141, bremelanotide, that is a commercial product right now that you can write as a prescription, okay? But that doesn't have the tanning benefit, but has the sexual, you know, benefits." (said at 0:53:34)

Bremelanotide (PT-141) was developed as an analogue/derivative of Melanotan II to target central melanocortin receptors (primarily MC4R) for sexual dysfunction. In 2019, the US FDA approved bremelanotide (under the brand name Vyleesi) as a prescription subcutaneous injection for premenopausal women with generalized hypoactive sexual desire disorder (HSDD), providing therapeutic sexual function benefits without being marketed or used for skin tanning.

0:54:14Alex Tatemsupportedhigh

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors.

"Well, believe it or not, the next blockbuster drug that Lilly is going to come out with probably in the next couple of months is this guy called retatrutide, all right? And retatrutide is fantastic in that it is the first three receptor agonist GLP-1 drug... Well, retatrutide adds in glucagon receptor activation." (said at 0:54:14)

Clinical trial evidence confirms that retatrutide (LY3437943), developed by Eli Lilly and Company, is a single peptide single-molecule triple hormone receptor agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) receptors.

0:55:07Alex Tatemsupportedhigh

Retatrutide's glucagon receptor activation combined with GLP-1 and GIP agonism leads to significant weight reduction and marked improvements in liver fat and NASH.

"But by stimulating the glucagon receptor while simultaneously hitting GLP-1 and GIP, what we found is not only do patients lose an incredible amount of weight, but they also get the best improvements we've ever seen in their liver health that we've ever seen." (said at 0:55:07)

In a randomized, double-blind, placebo-controlled phase 2 substudy evaluating retatrutide (a triple agonist of GLP-1, GIP, and glucagon receptors) in adults with metabolic dysfunction-associated steatotic liver disease (MASLD), retatrutide produced substantial dose-dependent weight loss (up to 24.2% weight reduction at 48 weeks) and marked reductions in liver fat content. At 24 weeks, the mean relative reduction in liver fat reached -81.4% with the 8 mg dose and -82.4% with the 12 mg dose (versus +0.3% with placebo), with 86% of patients in the 12 mg cohort achieving normalization of liver fat (<5%). Meta-analyses of incretin and polyagonist trials also highlight retatrutide as producing among the most pronounced liver fat reductions observed to date.

0:57:13Alex Tatemsupportedmoderate

CJC-1295 is a growth hormone-releasing hormone derivative and Ipamorelin is a ghrelin receptor agonist that synergistically stimulate growth hormone release.

"CJC-1295 being a growth hormone-releasing hormone derivative. And then we have Ipamorelin, which is a ghrelin receptor agonist. So again, improving the release of growth hormone through two different synergistic mechanisms." (said at 0:57:13)

CJC-1295 is a long-acting synthetic analog/derivative of growth hormone-releasing hormone (GHRH) that acts on pituitary GHRH receptors, while Ipamorelin is a selective growth hormone secretagogue receptor (GHSR-1a / ghrelin receptor) agonist. Co-activation of GHRH receptors (primarily activating adenylate cyclase and cAMP pathways) and ghrelin/GHS receptors (activating phospholipase C and intracellular calcium pathways) acts through distinct, complementary signaling cascades that synergistically stimulate pituitary growth hormone secretion.

0:58:25Alex Tatemsupportedmoderate

Excessive or long-term growth hormone abuse can cause insulin resistance and acromegalic bone changes to facial structure.

"Well, because if you take a little bit too much, you can actually get insulin resistance because your glucose levels will go too high for too long, all right? You abuse too much for too long, you will actually get acromegaly, so that's development of the your bones continue to grow, but not along, only in certain junctures. And so, there's a very specific look that bodybuilders who abuse growth hormone at high amounts will get to them, all right? Which is an irreversible change to the facial bone structure." (said at 0:58:25)

The claim is supported by endocrine and clinical toxicology literature. Chronic exposure to supraphysiological levels of growth hormone (GH), whether through endogenous hypersecretion or exogenous abuse for performance enhancement, directly reduces peripheral glucose uptake and increases insulin resistance. Furthermore, prolonged GH excess in adults stimulates periosteal bone growth and soft tissue proliferation, resulting in the characteristic acromegalic phenotype, including irreversible facial skeletal remodeling (such as frontal bossing and mandibular enlargement).

0:59:47Alex Tatemsupportedvery low

Epithalon works by enhancing telomerase activity to lengthen or protect cellular telomeres.

"So, epithalon, the purpose of it is it works to enhance telomerase." (said at 0:59:47)

In vitro laboratory studies demonstrate that the synthetic tetrapeptide Epithalon (Ala-Glu-Asp-Gly) induces expression of the catalytic subunit of telomerase, increases telomerase enzymatic activity, and promotes telomere elongation in cultured human somatic cells (such as human fetal fibroblasts). While this mechanism is documented in preclinical cell culture research, broad independent replication and human clinical evidence remain limited.

0:37:05Alex Tatemsupportedhigh

IGF-1 LR3 is a longer-lasting version of IGF-1, which is downstream of growth hormone.

"IGF-1 LR3 is basically the longer-lasting version of IGF-1, which is the downstream effect of growth hormone." (said at 0:37:05)

The claim is supported by endocrine literature. Growth hormone (GH) stimulates the hepatic production and release of insulin-like growth factor-1 (IGF-1), establishing IGF-1 as the primary downstream mediator of GH's somatotrophic effects within the GH-IGF-1 axis. IGF-1 Long R3 (IGF-1 LR3) is a synthetic recombinant analogue of IGF-1 modified with an N-terminal extension and an amino acid substitution (arginine for glutamic acid at position 3) that significantly reduces its binding affinity to IGF-binding proteins (IGFBPs), thereby preventing its rapid clearance and resulting in a longer duration of biological action relative to native IGF-1.

0:56:55Alex Tatemsupportedhigh

Growth hormone acts as a signal telling the liver to produce IGF-1.

"growth hormone acts like a signal that tells your liver to make more of another compound we talked about, IGF-1." (said at 0:56:55)

The statement is fully supported by established endocrinology. Growth hormone (GH) secreted by the pituitary gland acts on hepatic growth hormone receptors to stimulate the synthesis and secretion of insulin-like growth factor 1 (IGF-1), which accounts for the vast majority of circulating IGF-1.

0:53:23Alex Tatemsupportedmoderate

Melanotan II stimulates strong penile erections.

"It'll also give you some of the most impressive erections you've ever had in your life, so be warned." (said at 0:53:23)

Double-blind, placebo-controlled crossover clinical trials have confirmed that Melanotan II (a synthetic alpha-melanocyte-stimulating hormone analog) is a potent initiator of penile erections in men with both psychogenic and organic erectile dysfunction, as well as healthy volunteers. Across trials using RigiScan monitoring, subcutaneous administration of Melanotan II induced prolonged spontaneous erections, with subjects averaging over 38 to 45 minutes of greater than 80% penile tip rigidity in the absence of sexual stimulation.

0:59:18Alex Tatemsupportedhigh

Excess growth hormone can cause effusions into joint spaces leading to morning hand numbness.

"And if you take too much, it could potentially make your hands numb in the morning because you get effusions into the joint space." (said at 0:59:18)

Excess or exogenous growth hormone administration is well-documented to induce fluid retention, soft tissue edema, and arthralgias, frequently leading to carpal tunnel syndrome characterized by median nerve compression and hand numbness/paresthesias (which typically worsen at night and upon waking). Systematic reviews and randomized controlled trials evaluating growth hormone administration consistently identify peripheral edema, joint symptoms, and carpal tunnel syndrome as primary dose-related adverse effects.

1:00:30Alex Tatemsupportedmoderate

Shorter telomeres are associated with aging and potentially worse health outcomes.

"But, we know that shorter telomeres are associated with aging, potentially worse health outcomes." (said at 1:00:30)

Large-scale epidemiological studies and systematic reviews consistently demonstrate that leukocyte telomere length shortens with chronological age and that shorter telomeres are modestly associated with increased risks of adverse health outcomes, including all-cause mortality and age-related morbidities. A meta-analysis of cohort studies encompassing 121,749 individuals found that individuals in the shortest telomere length quartile had a 26% higher risk of all-cause mortality compared to those in the longest quartile.

1:00:40Alex Tatemsupportedlow

Telomerase is an enzyme that helps repair telomeres, and the peptide Epithalon encourages telomerase activity.

"Then, there's an enzyme that can help heal or repair the telomere called telomerase. Epithalon helps encourage that." (said at 1:00:40)

The claim is supported by in vitro and preclinical scientific literature. Telomerase is an enzyme (specifically a reverse transcriptase) that synthesizes telomeric DNA to maintain and repair shortened telomeres. Multiple laboratory studies demonstrate that Epithalon (also known as Epitalon or the tetrapeptide Ala-Glu-Asp-Gly/AEDG) induces hTERT expression, increases telomerase enzyme activity, and leads to telomere elongation in various cell types, including human somatic fibroblasts and bovine oocytes (PMID: 12937682, PMID: 40908429, PMID: 39788414). However, the certainty of evidence is low overall because evidence for Epithalon's effects on telomerase is limited to in vitro cell culture, animal models, and preliminary cell studies rather than robust randomized controlled trials in humans.

1:02:58Alex Tatemsupportedhigh

When stopping GLP-1 medications, patients regain lost weight unless lifestyle changes are maintained or they stay on a lower maintenance dose.

"We've looked at that. You actually regain the weight. And so cuz the truth is is that you have introduced something into your life that has moved the needle in one direction. But if you don't change anything else, well, you take that back out. Well, you're going to go back to where you were. And so if you're going to maintain that weight loss, you have to make lifestyle changes associated with that. And what we found is that people do regain if they do make lifestyle changes, they do regain some of the weight but not necessarily all of the weight. And there's also data showing that you could potentially stay on that medication but at a much lower dose and then maintain your weight, okay?" (said at 1:02:58)

Clinical trial evidence directly supports the speaker's claim that discontinuation of GLP-1 receptor agonists leads to weight regain unless therapy or lifestyle modifications are sustained. In the STEP 1 trial extension (Wilding et al., 2022), participants who stopped 68 weeks of once-weekly semaglutide 2.4 mg regained two-thirds of their lost weight (11.6 percentage points of the initial 17.3% loss) within one year. Similarly, in the STEP 4 trial (Rubino et al., 2021), participants switched to placebo (alongside lifestyle intervention) gained 6.9% body weight over 48 weeks, whereas those continuing semaglutide lost an additional 7.9%.

1:03:56Alex Tatemsupportedhigh

Clinical trials of retatrutide show a 20% to 25% loss of total body weight within a relatively short period of time.

"Because the changes in body composition that we have seen both in clinical trials, okay, and in anecdotal reports from users who have obtained on their own are wild. We're talking losing 20 to 25% of total body weight within a relatively short period of time." (said at 1:03:56)

A double-blind, randomized, placebo-controlled phase 2 clinical trial in 338 adults with overweight or obesity published in the New England Journal of Medicine demonstrated that once-weekly retatrutide produced substantial dose-dependent weight loss. At 48 weeks, participants receiving the higher doses achieved a least-squares mean body weight reduction of 22.8% (combined 8-mg dose) and 24.2% (12-mg dose), compared to 2.1% with placebo. At 24 weeks, mean weight loss had already reached 17.3% to 17.5% in the higher dose groups.

1:10:19Alex Tatemsupportedmoderate

GHK-Cu improves skin complexion and may offer small benefits for hair.

"Yeah. So this is, you know, probably the most well-known peptide for use for skin complexion, and I mean, really, it may have some small benefits when it comes to hair, all right? But those reports are a little bit more spotty." (said at 1:10:19)

The speaker's characterization is accurate. Copper tripeptide (GHK-Cu) is supported by clinical and cosmetic studies demonstrating improvements in skin elasticity, firmness, wrinkles, and hyperpigmentation/complexion. Evidence regarding hair growth is more limited and mixed, largely derived from hair follicle size increases in preclinical models, adjunctive use in hair transplantation, and pilot studies of multi-ingredient peptide formulations.

1:11:14Alex Tatemsupportedmoderate

Total motile sperm count, sperm concentration, and sperm quality in men have experienced a progressive decline since 1973.

"because what we're seeing is that back in 1973, total motile sperm count, so how many healthy swimming sperm do we have in each ejaculation, is exponentially higher and more dense than what we're seeing today. And so what we're seeing is a progressive decline in male fertility over time. And that's been demonstrated in multiple studies. We've debated this at multiple meetings. People have tried to argue that it's a measuring difference, but as we give it more time and as we give it more scrutiny, this is real. We're experiencing a significant decline in sperm quality and motility and concentration." (said at 1:11:14)

Large systematic reviews and meta-regression analyses confirm a progressive global decline in human sperm counts and concentrations since 1973. A comprehensive 2023 meta-analysis encompassing 223 studies (288 estimates from semen samples collected between 1973 and 2018) found that among men unselected by fertility, mean sperm concentration declined by 51.6% (from 101.2 to 49.0 million/ml) and total sperm count declined by 62.3%, with the rate of decline accelerating in recent decades. Earlier meta-analyses by the same group in 2017 observed a similar ~50–60% decline in Western cohorts over the 1973–2011 period.

1:12:39Alex Tatemsupportedmoderate

Insulin resistance, metabolic disease, and obesity are the primary modifiable risk factors driving the decline in male fertility and sperm parameters.

"So, the leading culprits are going to be, yes, microplastics and environmental toxins. Okay, things that are put in our environment that we have been exposed to that we can't help. But again, the biggest modifiable risk factor is insulin resistance and metabolic disease. Obesity." (said at 1:12:39)

Systematic reviews and meta-analyses demonstrate that obesity, metabolic syndrome, and impaired glucose metabolism are among the most significant modifiable contributors to declines in semen parameters (including sperm count, concentration, progressive motility, morphology, and DNA integrity) and reproductive outcomes. While other modifiable factors (such as smoking and specific toxic exposures) also play substantial roles, the characterization of obesity and metabolic disease as primary modifiable drivers is well-supported across observational and interventional andrology literature.

1:19:29Alex Tatemsupportedmoderate

World Anti-Doping Agency data indicates that up to 40% of Olympic-level athletes currently use or have used banned performance-enhancing substances.

"the Enhanced Games is a project based off of the World Anti-Doping Agency's own data. Potentially up to 40% of athletes that are competing at the Olympic level have either are currently using or have used banned substances at some point in time, all right?" (said at 1:19:29)

The statement accurately reflects findings from research commissioned under the auspices of the World Anti-Doping Agency (WADA). A landmark study using randomized-response technique surveys administered to 2,167 elite international athletes at the 2011 World Championships in Athletics (WCA) and the Pan-Arab Games estimated that 43.6% (95% CI 39.4–47.9%) of elite track and field athletes had engaged in doping within the past year. A systematic review by the WADA Working Group on Doping Prevalence confirmed that while standard biological drug tests only detect 1–2% positive samples, indirect survey methods at elite competitions have estimated past-year doping rates exceeding 40%.

1:20:43Alex Tatemsupportedmoderate

The International Olympic Committee does not pay prize money to athletes for winning Olympic medals.

"They don't get paid to compete at all, okay? So, they don't get paid to be an Olympic athlete. They uh end up getting sponsorship deals and that's potentially the money that they can make." (said at 1:20:43)

The International Olympic Committee (IOC) does not directly pay prize money or salaries to athletes for competing or winning medals at the Olympic Games. Under Olympic governance, athletes are not employed by the IOC or National Olympic Committees to compete, and athletes in non-professional leagues rely on sponsorships, national development programs, or independent funding, leading to growing demands from athletes for direct remuneration and revenue sharing from major competitions.

1:23:32Alex Tatemsupportedmoderate

Long-term metabolic dysfunction and vascular disease lead to penile atrophy and size loss.

"But, the problem is that when you have long-term metabolic and vascular dysfunction, the brake lines, the blood vessels that feed those erections, they fail. And all of a sudden, you can't get enough blood flow for it to work. And believe it or not, you can actually get atrophy of the penis over time, and you actually lose size, all right?" (said at 1:23:32)

Published urological literature supports the claim that chronic vascular and metabolic dysfunction impairs penile arterial inflow, resulting in tissue hypoxia, apoptosis of cavernous smooth muscle, and progressive corporal fibrosis. Over time, the loss of functional cavernous smooth muscle and replacement by collagenous extracellular matrix lead to penile structural atrophy and measurable loss of penile length and girth.

1:24:57Alex Tatemsupportedmoderate

Penile prosthesis implantation does not affect penile sensation because the sensory nerves run along the dorsal aspect (12 o'clock position) of the penis.

"Yeah. So it does not affect sensation. And so the nerves that affect sensation run along the top of the penis. If you're looking at a clock, at the 12:00 position, and we stay totally away from those." (said at 1:24:57)

Penile prosthesis implantation (PPI) is designed to preserve penile sensation because the sensory fibers (the dorsal nerves of the penis) run along the dorsal aspect (the 12 o'clock position) beneath Buck's fascia, whereas the prosthesis cylinders are surgically placed within the corporal bodies (corpora cavernosa) via corporotomies that avoid the dorsal neurovascular bundle. Electrophysiological and clinical studies evaluating nerve conduction velocity (NCV) before and after PPI demonstrate that significant loss of penile sensation does not occur following surgery.

1:25:33Alex Tatemsupportedmoderate

There are approximately 30 million men with erectile dysfunction in the United States.

"If you look at in the United States right now, okay, there are 30 million men with erectile dysfunction in the United States right now. That's more than the population of Australia, all right?" (said at 1:25:33)

Epidemiological estimates and clinical reviews widely report that approximately 30 million men in the United States are affected by erectile dysfunction, largely based on population-based extrapolations such as the Massachusetts Male Aging Study (MMAS). More conservative nationally representative surveys (e.g., NHANES 2001–2002) estimated that 18 million adult men have erectile dysfunction when using strict definitions, with broader definitions accounting for mild-to-moderate dysfunction encompassing up to 30 million.

1:04:51Alex Tatemsupportedhigh

The developmental patent and intellectual property rights for the multi-receptor agonist retatrutide are owned solely by Eli Lilly.

"No, no, that is going to belong solely to Lilly." (said at 1:04:51)

Retatrutide (development code LY3437943) is a proprietary triple hormone receptor agonist (targeting GLP-1, GIP, and glucagon receptors) discovered and developed internally by Eli Lilly and Company, which sponsors its clinical trials and holds the underlying intellectual property and developmental rights.

1:14:44Alex Tatemsupportedhigh

Peyronie's disease is a condition characterized by fibrous scar tissue or damage inside the penis that causes penile curvature.

"Peyronie's disease, which is damage to the penis that causes curvature" (said at 1:14:44)

Peyronie's disease is an established urological condition characterized by microvascular trauma and an abnormal wound-healing response leading to fibrous scar tissue (plaques) within the tunica albuginea of the penis, which results in penile curvature, pain, and deformity during erection.

5

No source found (not proven false)

0:01:22Alex Tatemunverifiedvery low

Methylene blue stains nails blue and hair blue when taken.

"There's methylene blue where people take it and they think it's going to make them live forever. Don't take this. It literally will stain your nails blue and your hair blue." (said at 0:01:22)

No published record matching the claim that taking methylene blue stains nails and hair blue was located; this does not prove the claim false. While systemic administration of methylene blue commonly causes blue-green discoloration of urine (chromaturia) and can cause transient bluish discoloration of the skin, saliva, or mucous membranes, published clinical evidence demonstrating that oral ingestion causes blue discoloration of the hair or nail plates is lacking.

0:13:50Alex Tatemunverifiedvery low

In 2023, the FDA shifted 19 popular peptides from Category 1 to Category 2 for compounding, effectively banning compounding pharmacies from producing them.

"And all of these original compounds, these peptides that we're so interested in now, were originally on that first list, Category 1, all right? And so, they were able to be compounded... But then in 2023, the FDA at that time switched all of those peptides, 19 of them that were popular, to Category 2, and then they were banned." (said at 0:13:50)

No published record matching the claim that the FDA shifted 19 peptides from Category 1 to Category 2 in 2023 to prohibit compounding was located; this does not prove the claim false.

0:22:42Alex Tatemunverifiedvery low

A patient with obesity and metabolic dysfunction increased his sperm count tenfold into normal range after losing 100 pounds using tirzepatide alongside diet and exercise.

"And I just saw a patient last week who increased his sperm count 10 times over and is now in a normal range because he's lost 100 pounds due to using tirzepatide, exercising, and improving his diet." (said at 0:22:42)

No published record matching this specific clinical case of a patient increasing his sperm count tenfold into normal range after losing 100 pounds with tirzepatide, diet, and exercise was located; this does not prove the claim false. While obesity is well recognized to impair spermatogenesis and substantial weight loss combined with lifestyle intervention can improve reproductive hormones and semen parameters, direct clinical trial evidence evaluating the specific effects of tirzepatide on human semen parameters remains limited.

0:42:28Alex Tatemunverifiedvery low

Selank promotes calming and enhances restorative deep delta brain waves during sleep.

"things like Selank, which is another one that can help calm you as you're going to sleep about an hour ahead of time. And again, help those deep delta wave brain waves that are so restorative whenever you actually are, you know, resting." (said at 0:42:28)

While Selank (a synthetic heptapeptide analogue of tuftsin) has been studied in preliminary and Russian clinical literature as an anxiolytic agent that modulates GABA receptors, no published record matching the claim that Selank enhances restorative deep delta brain waves during sleep was located; this does not prove the claim false. The speaker may have conflated Selank with delta sleep-inducing peptide (DSIP), a distinct peptide studied for slow-wave sleep induction.

0:46:25Alex Tatemunverifiedvery low

Obesity rates in the United States are estimated between 40% and 70% depending on the BMI cutoff used.

"the unfortunate reality is that here in the United States, it depends on what database you look at, but obesity rates are estimated to be 40 to 70%, okay? Depending on what BMI cutoff you're using, okay?" (said at 0:46:25)

No published record matching the claim that obesity rates in the United States are estimated between 40% and 70% depending on the BMI cutoff used was located; this does not prove the claim false.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.